COVID-19 Vaccines Relative Attribute Importance: Insights on Preference Heterogeneity Identified Through Latent Class Modeling
Author(s)
Lazarus J1, Waite N2, Salisbury D3, Lehmann C4, Sri Bhashyam S5, d la Cruz M6, Hahn B7, Beyhaghi H8, Rousculp M9, Bonanni P10
1Hospital Clinic, University of Barcelona, Barcelona, Barcelona, Spain, 2University of Waterloo, Waterloo, ON, Canada, 3Royal Institute of International Affairs, Chatham House, London, London, UK, 4University of Cologne, Albertus-Magnus-Platz, 50923 Köln, Germany, 5ICON Plc, Reading, RDG, UK, 6ICON Plc, Raleigh, NC, USA, 7Novavax Inc, Gaithersburg, MD, USA, 8Novavax, Inc., Gaithersburg, MD, USA, 9Novavax Inc., Gaithersburg, MD, USA, 10University of Florence, 50121 Firenze, Florence, Italy
Presentation Documents
OBJECTIVES: Data suggest a proportion of the population remains hesitant to receive COVID-19 vaccination. We used a discrete choice experiment (DCE) to understand the vaccine attributes that adults value most.
METHODS: An online survey of 2000 adults in Canada, Germany, the United Kingdom and the United States was conducted between July and August 2023, which included a DCE within a broader COVID-19 survey. The DCE presented two hypothetical vaccine options and an opt-out option in the form of 11 vaccine profiles. Six attributes were tested: vaccine type, protection against COVID-19 infection, protection against severe COVID-19 disease, chances of experiencing common side-effects (i.e., reactogenicity events), serious side-effects (e.g., myocarditis/pericarditis), and timing of COVID-19 vaccines with influenza vaccine. Relative attribute importance (RAI) and trade-offs were calculated. Heterogeneity was investigated using a latent class model.
RESULTS: In the pooled sample, three classes best explained the variability in participant RAIs. Class 1 (40.0%) was driven by vaccine efficacy considerably more than the other classes; Class 2 (9.0%) had a more even concern between efficacy, safety and the timing of the vaccine; Class 3 (51.0%) placed similar importance on efficacy and avoiding common side-effects.
In the subgroup at higher risk of sequela of infections, class 1 (89%) was highly driven by efficacy; class 2 placed greater emphasis on protection against severe disease and serious side-effects and preferred separate injections. In the vaccine-hesitant subgroup, class 1 (85.0%) was driven by efficacy, and avoiding common side-effects; class 2 (15.0%) was almost equally concerned with efficacy and safety attributes combined.CONCLUSIONS: These findings show that distinct cohorts exist with varying attitudes towards efficacy and risk attributes. Given the concern of common side-effects in most participants, the nature of common side-effects should be communicated to inform people making their seasonal COVID-19 vaccine decisions.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
PCR298
Topic
Patient-Centered Research, Study Approaches
Topic Subcategory
Patient Behavior and Incentives, Stated Preference & Patient Satisfaction, Surveys & Expert Panels
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines